In addition to primary end point, other sub-groups of interest for me are: 1. tg>250, 2. secondary prevention, 3. diabetes, 4. mixed dyslipidemia, 5. CKD/renal, 6. PAD, 7. hsCRP>3

amrn 可能远远被市场低估了。这实验非常巨大。